Vernalis PLC Total Voting Rights (8342X)

TIDMVER

RNS Number : 8342X

Vernalis PLC

28 February 2017

TOTAL VOTING RIGHTS

VERNALIS PLC (the "Company")

28 February 2017

Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,366,293 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.

The total number of voting rights in the Company is therefore 526,366,293.

The above figure of 526,366,293 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company.

- ends -

Enquiries:

 
                                    [phone] 
 Vernalis plc:                                 0015 
 Ian Garland, Chief Executive 
  Officer 
  David Mackney, Chief Financial 
  Officer 
 Canaccord Genuity Limited          [phone] 
  (Nominated Adviser):                         8000 
 Henry Fitzgerald-O'Connor 
  Emma Gabriel 
                                    [phone] 
 Shore Capital (Joint Broker):                 4090 
 Bidhi Bhoma 
  Toby Gibbs 
                                    [phone] 
 FTI Consulting:                               1000 
 Ben Atwell 
  Simon Conway 
  Stephanie Cuthbert 
 

Notes to Editors

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra(R) XR targeting the US prescription cough cold market; Moxatag(R) , a daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adult and paediatric patients 12 years of age or older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho and Tris.

For further information about Vernalis, please visit www.vernalis.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRUSRVRBAAUUAR

(END) Dow Jones Newswires

February 28, 2017 02:00 ET (07:00 GMT)